Efeitos do 2-nitrato-1,3-di(octanoxi)propano (NDOP) em aorta de camundongo C57BL/6.

• Autor(a) principal: Paula, Ricardo Bernardino de
• Data de Publicação: 2016
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Biblioteca Digital de Teses e Dissertações da UFPB
• Texto Completo: https://repositorio.ufpb.br/jspui/handle/tede/8840
• topic: Nitratos orgânicos; Ôxido nítrico; Canais para K+; Vasorrelaxamento; Toxicidade; Organic nitrates; Nitric oxide; K+ channels; Vasorelaxant; Toxicity; CIENCIAS BIOLOGICAS

Organic nitrates have been used in cardiovascular disorders therapy because they work as nitric oxide (NO) donors. The present study aimed to characterize the 2-nitrate-1,3-dioctanoxypropan (NDOP), an organic nitrate synthesized from glycerin as a NO donor. The ability of NO release elicited by NDOP was evaluated in vascular smooth muscles cells (VSMC) from aorta and in vascular reactivity essays in thoracic aorta rings from C57BL/6 mice pre-contracted with phenylephrine. In addition, in vitro tolerance for NDOP and the acute pre-clinical toxicity to its oral administration (v.o.) (300 and 2000 mg/kg) were evaluated. The treatment with NDOP increased NO levels in VSMC when compared to cells stimulated with DAF probe only (53,20 ± 1,61 vs. 10,74 ± 0,86 a.u., n = 13 and 13, respectively, p < 0.05). The NO increase in VSMC was not inhibited by endothelial nitric oxide synthase (eNOS) inhibitor, L-NG-Nitroarginine (L-NNA, 100 μM) (52,80 ± 2,89 vs. 53,75 ± 2,18 a.u., n = 13 each). NDOP (10-8 – 10-3 M) induced endothelium-independent vasorelaxant effect in aorta from mice (Emax = 102,6 ± 1,7% vs. 107,3 ± 7,5%, n = 8 and 6, respectively). Pre-incubation with NOS blocker, L-NAME (100 μM) did not change the vasorelaxant response in functional endothelium rings (Emax= 112,5 ± 7,4%, n = 7). However the vasorelaxant effect to NDOP in rings without functional endothelium was decreased by pre-treatment with NO scavenger, 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl 3-oxide (PTIO, 300 μM) (Emax= 75,7 ± 5,6%, n = 7, p < 0.05) and by PTIO + hydroxocobalamin (Emáx= 38,8 ± 4,6%, n = 4, p < 0.05). The soluble guanylyl cyclase (sGC) selective inhibitor, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 10 μM), reduced the NDOP vasorelaxant response (Emáx = 22,2 ± 6,7%, n = 6, p < 0.05). When rings were contracted with modified Krebs solution by KCl 60 mM, NDOP maximum relaxation efficiency was attenuated (Emax = 80,4 ± 5,2%; n = 6, p < 0,05). The unspecified inhibition of potassium channels (K+) using Krebs depolarizing solution in addition to KCl 20 mM reduced the efficiency of relaxation induced by NDOP (Emax= 72,8 ± 3,4%; n = 6, p < 0.05). Specific blocking of BKca by TEA (1 mM), Kv by 4-aminopyridine (4-AP; 1 mM) or KATP by glybenclamide (GLIB, 10 μM) did not change the standard relaxing curve for NDOP. However, the pre-incubation with barium chloride (BaCl2, 30 μM), an inward-rectifier potassium channels (KIR) blocker reduced the relaxation effect induced by NDOP (Emax= 73,7 ± 5,7%, n = 6, p <0.05). In aorta rings pre-incubation with NDOP (10-4 M), the vasorelaxation induced by NDOP was reduced in rings with endothelium (Emax= 49,4 ± 3,5% vs. 102,6 ± 1,7%; n = 7 and 8, respectively, p < 0.05) and without endothelium (Emax= 44,1 ± 5,9% vs. Emax= 107.3 ± 7.5%, n = 6 and 6, respectively, p < 0.05). Oral administration of NDOP (300 and 2000 mg/kg) in female mice demonstrated that the compound present low pre-clinical acute toxicity and the DL50 was about 5000 mg/kg. The results demonstrate that NDOP acts as a NO donor in VSMC and produce vasorelaxation via NO-cGMP-PKG pathway and activation of KIR channels. However, although the low pre-clinical acute toxicity, NDOP demonstrate to induce vascular tolerance in vitro.